The novel small molecule CGRP receptor antagonists (gepants) can safely be added as attack treatment during preventive anti-CGRP/rec mAbs treatment [111, 112] and co-administration in migraine patients did not influence the pharmacokinetics or safety of ubrogepant [113]. Here, CALCA is linked to migraine disorder.